Clinicopathological analysis of 38 male patients diagnosed with breast cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: IOS Press Country of Publication: Netherlands NLM ID: 8801277 Publication Model: Print Cited Medium: Internet ISSN: 1558-1551 (Electronic) Linking ISSN: 08886008 NLM ISO Abbreviation: Breast Dis Subsets: MEDLINE
    • Publication Information:
      Publication: Amsterdam : IOS Press
      Original Publication: [New York, NY] : Elsevier, [c1987-
    • Subject Terms:
      Breast Neoplasms*/pathology ; Breast Neoplasms, Male*/pathology ; Bone Neoplasms* ; Carcinoma, Ductal, Breast*/pathology; Humans ; Male ; Aged ; Prognosis ; Lymph Nodes/pathology ; Receptors, Progesterone
    • Abstract:
      Background: Male breast cancer (MBC) accounts for one percent of all breast cancers. Due to the lack of awareness and routine screening programs, most patients present with systemic disease at the time of diagnosis with low overall survival.
      Objectives: This study aims to investigate the prognostic factors of male breast cancer and its correlation with established prognostic parameters and patient outcomes.
      Methods: Thirty-eight male breast cancer patients are identified from the MKA Breast Cancer Clinic database, and their corresponding clinical and pathological characteristics are obtained. Cut-off values of 1% and 10% are applied to further classify ER and PR results.
      Results: Older men are more likely to develop MBC than younger men and are more likely to have spread to axillary lymph nodes. Invasive ductal carcinoma is a more common histologic type in MBC. All the tested patients have ER and PR positivity. Distant metastasis developed in 17/38 (44.7%) patients. Bone metastasis is seen commonly in metastatic MBC.
      Conclusions: According to our cohort, MBC is seen in older males, presents in later stages, and shows hormone receptor positivity and a tendency to bone involvement. MBC is a heterogenous but distinct biological entity requiring a specific clinical and pathological approach.
    • References:
      Sci Rep. 2017 Mar 28;7:45293. (PMID: 28350011)
      Cancer Causes Control. 2004 Aug;15(6):571-80. (PMID: 15280636)
      Prostate Cancer Prostatic Dis. 2009;12(1):52-6. (PMID: 18504455)
      Breast Cancer Res Treat. 2019 Jan;173(1):37-48. (PMID: 30267249)
      Cancer. 1955 Nov-Dec;8(6):1239-50. (PMID: 13270243)
      J Oncol. 2022 May 24;2022:1734049. (PMID: 35656339)
      Nat Genet. 2002 May;31(1):55-9. (PMID: 11967536)
      Ann Oncol. 2018 Feb 1;29(2):405-417. (PMID: 29092024)
      J Am Coll Radiol. 2018 Nov;15(11S):S313-S320. (PMID: 30392600)
      Oncologist. 2005 Aug;10(7):471-9. (PMID: 16079314)
      Cancer. 2004 Jul 1;101(1):51-7. (PMID: 15221988)
      JAMA Oncol. 2019 Nov 01;5(11):1589-1596. (PMID: 31536134)
      Endocr Relat Cancer. 2017 Mar;24(3):R27-R34. (PMID: 28062545)
      Breast Cancer Res Treat. 2020 Apr;180(2):481-490. (PMID: 32056055)
      Ann Oncol. 2013 Sep;24(9):2206-23. (PMID: 23917950)
      J Breast Health. 2016 Jan 01;12(1):1-8. (PMID: 28331724)
      Anticancer Res. 1997 Nov-Dec;17(6D):4293-7. (PMID: 9494523)
      Cancer Res. 2011 Mar 15;71(6):2222-9. (PMID: 21285249)
      Cancer. 2010 Aug 1;116(15):3558-68. (PMID: 20564105)
      Eur J Breast Health. 2019 Jul 01;15(3):141-146. (PMID: 31312788)
      BMC Cancer. 2002 Oct 16;2:26. (PMID: 12383352)
      J Natl Cancer Inst. 1991 Jun 19;83(12):849-54. (PMID: 2061945)
      Surg Clin North Am. 1996 Apr;76(2):343-63. (PMID: 8610268)
      J Clin Oncol. 2011 Nov 20;29(33):4381-6. (PMID: 21969512)
      Cancer. 1998 Aug 1;83(3):498-509. (PMID: 9690543)
      Breast Cancer Res Treat. 2005 Sep;93(2):145-50. (PMID: 16187234)
      Ann Oncol. 2017 Dec 1;28(12):3111. (PMID: 28327998)
      Mod Pathol. 2017 Apr;30(4):509-518. (PMID: 28084333)
      Cancer. 2005 Dec 1;104(11):2359-64. (PMID: 16270318)
      Breast Cancer Res Treat. 2011 Oct;129(3):747-60. (PMID: 21113657)
      Am J Surg. 2001 Feb;181(2):96-100. (PMID: 11425067)
      Curr Oncol Rep. 2016 Jan;18(1):1. (PMID: 26694922)
      Am J Surg. 1995 Jul;170(1):24-6. (PMID: 7793489)
      J Natl Compr Canc Netw. 2021 Jan 06;19(1):77-102. (PMID: 33406487)
      Breast Cancer Res. 2010;12(3):R42. (PMID: 20576095)
      Breast Care (Basel). 2008;3(3):183-189. (PMID: 20824037)
      Cancer Cell. 2006 Dec;10(6):529-41. (PMID: 17157792)
      Breast Cancer Res. 2002;4(1):R2. (PMID: 11879560)
      Ann Intern Med. 2002 Oct 15;137(8):678-87. (PMID: 12379069)
      Int J Cancer. 1993 Feb 20;53(4):538-49. (PMID: 8436428)
      Clin Breast Cancer. 2000 Apr;1(1):57-63; discussion 64-5. (PMID: 11899391)
      Am J Gastroenterol. 1998 Feb;93(2):231-3. (PMID: 9468249)
      Lancet. 2006 Feb 18;367(9510):595-604. (PMID: 16488803)
      BMC Genomics. 2006 Apr 27;7:96. (PMID: 16643655)
      Eur J Cancer Prev. 2002 Jun;11(3):253-63. (PMID: 12131659)
    • Contributed Indexing:
      Keywords: Male; breast cancer; prognostic parameters; survival
    • Accession Number:
      0 (Receptors, Progesterone)
    • Publication Date:
      Date Created: 20240216 Date Completed: 20240219 Latest Revision: 20240227
    • Publication Date:
      20240227
    • Accession Number:
      PMC10894578
    • Accession Number:
      10.3233/BD-230050
    • Accession Number:
      38363600